Tris hcl buffer

The enantiomeric excess (S)-CypL (the enantiomeric mixture of CypL; lot number: L1816) was from NanoLight Technology, Prolume (Pinetop, AZ, USA) (see Supplementary Figure S1 and Table S1). Human AGP (alpha 1-acid glycoprotein form human plasma) and potassium hexafluorophosphate were from Sigma-Aldrich (St. Louis, MO, USA). Tris–HCl buffer, l-ascorbic acid sodium salt, and sodium chloride were from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). All materials were used without further purification. Racemic CypL and (S)-CypL were prepared according to the method reported previously [19 (link),20 (link)]. A recombinant CypLase from C. noctiluca was prepared using plant cells according to the method reported previously (see Supplementary Figure S2) [14 (link)]. The concentrations of CypL solutions were determined spectrophotometrically using a spectrophotometer (V-660; Jasco, Tokyo, Japan), according to the reported molar absorption coefficient [24 (link)]. The concentrations of Human AGP and recombinant CypLase solutions were determined by SDS-PAGE analysis or by using the corresponding molar extinction coefficient at 280 nm, as calculated via the peptide property calculator available at https://www.biosyn.com/peptidepropertycalculator/peptidepropertycalculator.aspx (accessed on 6 October 2023).